BACKGROUND AND PURPOSE: Stroke treatment is constrained by limited treatment windows and the clinical inefficacy of agents that showed preclinical promise. Yet animal and clinical data suggest considerable poststroke plasticity, which could allow treatment with recovery-modulating agents. Memantine is a well-tolerated N-methyl-D-aspartate glutamate receptor antagonist in common use for Alzheimer disease. METHODS: Memantine, 30 mg/kg per day, or vehicle, was delivered chronically in drinking water beginning >2 hours after photothrombotic stroke. RESULTS: Although there was no difference in infarct size, behavior, or optical intrinsic signal maps in the first 7 days after stroke, mice treated chronically with memantine showed significant improvements in motor control, measured by cylinder test and grid-walking performance, compared with vehicle-treated animals. Optical intrinsic signal revealed an increased area of forepaw sensory maps at 28 days after stroke. There was decreased reactive astrogliosis and increased vascular density around the infarcted cortex. Peri-infarct Western blots revealed increased brain-derived neurotrophic factor and phosphorylated-tropomyosin-related kinase-B receptor expression. CONCLUSIONS: Our results suggest that memantine improves stroke outcomes in an apparently non-neuroprotective manner involving increased brain-derived neurotrophic factor signaling, reduced reactive astrogliosis, and improved vascularization, associated with improved recovery of sensory and motor cortical function. The clinical availability and tolerability of memantine make it an attractive candidate for clinical translation.
BACKGROUND AND PURPOSE:Stroke treatment is constrained by limited treatment windows and the clinical inefficacy of agents that showed preclinical promise. Yet animal and clinical data suggest considerable poststroke plasticity, which could allow treatment with recovery-modulating agents. Memantine is a well-tolerated N-methyl-D-aspartate glutamate receptor antagonist in common use for Alzheimer disease. METHODS:Memantine, 30 mg/kg per day, or vehicle, was delivered chronically in drinking water beginning >2 hours after photothrombotic stroke. RESULTS: Although there was no difference in infarct size, behavior, or optical intrinsic signal maps in the first 7 days after stroke, mice treated chronically with memantine showed significant improvements in motor control, measured by cylinder test and grid-walking performance, compared with vehicle-treated animals. Optical intrinsic signal revealed an increased area of forepaw sensory maps at 28 days after stroke. There was decreased reactive astrogliosis and increased vascular density around the infarcted cortex. Peri-infarct Western blots revealed increased brain-derived neurotrophic factor and phosphorylated-tropomyosin-related kinase-B receptor expression. CONCLUSIONS: Our results suggest that memantine improves stroke outcomes in an apparently non-neuroprotective manner involving increased brain-derived neurotrophic factor signaling, reduced reactive astrogliosis, and improved vascularization, associated with improved recovery of sensory and motor cortical function. The clinical availability and tolerability of memantine make it an attractive candidate for clinical translation.
Authors: Xiaoling Li; Kathleen K Blizzard; Zhiyuan Zeng; A Courtney DeVries; Patricia D Hurn; Louise D McCullough Journal: Exp Neurol Date: 2004-05 Impact factor: 5.330
Authors: Andy Y Shih; Pablo Blinder; Philbert S Tsai; Beth Friedman; Geoffrey Stanley; Patrick D Lyden; David Kleinfeld Journal: Nat Neurosci Date: 2012-12-16 Impact factor: 24.884
Authors: Maria Ek Lie; Emma K Gowing; Nina B Johansen; Nils Ole Dalby; Louise Thiesen; Petrine Wellendorph; Andrew N Clarkson Journal: J Cereb Blood Flow Metab Date: 2017-11-21 Impact factor: 6.200
Authors: Andrew N Clarkson; Lily Boothman-Burrell; Zita Dósa; Raghavendra Y Nagaraja; Liang Jin; Kim Parker; Petra S van Nieuwenhuijzen; Silke Neumann; Emma K Gowing; Navnath Gavande; Philip K Ahring; Mai M Holm; Jane R Hanrahan; Joseph A Nicolazzo; Kimmo Jensen; Mary Chebib Journal: J Cereb Blood Flow Metab Date: 2018-01-29 Impact factor: 6.200
Authors: Volodymyr B Bogdanov; Natalie A Middleton; Jeremy J Theriot; Patrick D Parker; Osama M Abdullah; Y Sungtaek Ju; Jed A Hartings; K C Brennan Journal: J Neurosci Date: 2016-04-27 Impact factor: 6.167